featured
Second-Line FOLFOX Chemotherapy vs Active Symptom Control for Advanced Biliary Tract Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Oncology